NXL (Nexalin Technology) FCF Margin % : -2,297.22% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Nexalin Technology FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nexalin Technology's Free Cash Flow for the three months ended in Sep. 2024 was $-0.83 Mil. Nexalin Technology's Revenue for the three months ended in Sep. 2024 was $0.04 Mil. Therefore, Nexalin Technology's FCF Margin % for the quarter that ended in Sep. 2024 was -2,297.22%.

As of today, Nexalin Technology's current FCF Yield % is -7.30%.

The historical rank and industry rank for Nexalin Technology's FCF Margin % or its related term are showing as below:

NXL' s FCF Margin % Range Over the Past 10 Years
Min: -3553.15 Med: -551.74 Max: -167.75
Current: -2396.32

During the past 4 years, the highest FCF Margin % of Nexalin Technology was -167.75%. The lowest was -3553.15%. And the median was -551.74%.

NXL's FCF Margin % is ranked worse than
95.88% of 825 companies
in the Medical Devices & Instruments industry
Industry Median: -4.42 vs NXL: -2396.32

Nexalin Technology FCF Margin % Historical Data

The historical data trend for Nexalin Technology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nexalin Technology FCF Margin % Chart

Nexalin Technology Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-355.56

-747.92

-167.75

-3,553.15

Nexalin Technology Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial											-3,375.00	-4,490.48	-1,049.37	-4,840.74	-2,297.22

Competitive Comparison of Nexalin Technology's FCF Margin %

For the Medical Devices subindustry, Nexalin Technology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nexalin Technology's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nexalin Technology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nexalin Technology's FCF Margin % falls into.

Nexalin Technology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nexalin Technology's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-3.944	/	0.111
	=	-3,553.15 %

Nexalin Technology's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-0.827	/	0.036
	=	-2,297.22 %

Nexalin Technology FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nexalin Technology's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nexalin Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nexalin Technology Inc (NAS:NXL) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1776 Yorktown, Suite 550, Houston, TX, USA, 77056

Website

https://www.nexalin.com

Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Executives

David Owens	director, officer: Chief Medical Officer	4545 HARRIS TRAIL NW, ATLANTA GA 30327
Marilyn Elson	10 percent owner, officer: Ms. Elson serves as CFO	32 CAMLET COURT, ROSELAND NJ 07068
Rick Morad	director	6331 CHAGRIN RIVER ROAD, BENTLEYVILLE OH 44022
Mark White	director, officer: President/CEO	1776 YORKTOWN STREET, SUITE 550, HOUSTON TX 77056
Alan Kazden	director	3435 CONSUELO DRIVE, CALABASAS CA 91302
Leonard Osser	other: Spouse
Ben Hu	director	7021 EDGERTON ROAD, NORTH ROYALTON OH 44133